Nanoparticle Albumin Bound Paclitaxel in the Treatment of Human Cancer: Nanodelivery Reaches Prime-Time?

Abstract

Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.

A comprehensive review of the neonatal Fc receptor and its application in drug delivery

“…The nab-technology was initially used for metastatic breast cancer, being currently in trials for treatment of non-small lung cancer, pancreas cancer, and melanoma (Cucinotto et al, 2013;Elsadek and Kratz, 2012;Hersh et al, 2010;Kottschade et al, 2011Kottschade et al, , 2013Kratz, 2014;Miele et al, 2009;Petrelli et al, 2010;Sand et al, 2015). The technology as such consists of mixing a lipophilic drug with human serum albumin in an aqueous solvent.…”

Untitled

“…Furthermore, nab-paclitaxel has been shown to reduce drug exposure to healthy tissue [43]. In addition, the intravenous infusion was reported to be controlled and safer compared with paclitaxel due to the use of standard plastic intravenous bags which are possible to reconstitute in smaller volume of normal saline [56].…”

Prostate Cancer Imaging and Therapy: Potential Role of Nanoparticles

“…Albumin is a natural carrier of hydrophobic molecules that allows the transport of these molecules around the body and their release at the cell surface (15). Nab-paclitaxel is a colloidal suspension, homogenized with human serum albumin (3%-4%), by which it is possible to infuse higher doses of the drug than the standard dose with fewer side effects, reduced infusion time, and no premedication (16). The formulation enhances intracellular antitumor delivery and activity (17) and has led to a change in the treatment algorithm of breast cancer, pancreatic cancer, and melanoma.…”